Olipudase alfa
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sphingomyelin Lipidosis
Conditions
Sphingomyelin Lipidosis
Trial Timeline
May 1, 2015 → Dec 9, 2019
NCT ID
NCT02292654About Olipudase alfa
Olipudase alfa is a phase 1/2 stage product being developed by Sanofi for Sphingomyelin Lipidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02292654. Target conditions include Sphingomyelin Lipidosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06192576 | Pre-clinical | Recruiting |
| NCT05359276 | Pre-clinical | Completed |
| NCT06949358 | Phase 2 | Completed |
| NCT02292654 | Phase 1/2 | Completed |
Competing Products
6 competing products in Sphingomyelin Lipidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Recombinant human acid sphingomyelinase | Sanofi | Phase 1 | 32 |
| Olipudase alfa | Sanofi | Pre-clinical | 22 |
| placebo (saline) + Olipudase alfa | Sanofi | Phase 2/3 | 64 |
| GZ402665 | Sanofi | Phase 2 | 51 |
| olipudase alfa (GZ402665) | Sanofi | Pre-clinical | 22 |
| rhASM + rhASM + rhASM + rhASM + rhASM | Sanofi | Phase 1 | 32 |